Viscum album, as alternative and bridge to palliative chemotherapy in recurrent gallbladder cancer following laparoscopic radical cholecystectomy: a case report.
Chemotherapy
Drug therapy
Gallbladder neoplasms
Recurrence
Viscum album
Journal
Korean journal of clinical oncology
ISSN: 2288-4084
Titre abrégé: Korean J Clin Oncol
Pays: Korea (South)
ID NLM: 9918521386106676
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
29
09
2023
accepted:
16
11
2023
medline:
17
1
2024
pubmed:
17
1
2024
entrez:
17
1
2024
Statut:
ppublish
Résumé
A 78-year-old female patient was initially treated with laparoscopic radical cholecystectomy for gallbladder cancer (pT2aN1M0, stage IIIB). The patient then received adjuvant chemotherapy with gemcitabine. After completion of adjuvant chemotherapy, multiple lymph node metastases were observed in follow-up computed tomography (CT) scan, but the patient refused to go through further chemotherapy. One year after the recurrence, carbohydrate antigen 19-9 (CA19-9) level was 1,925 U/mL with follow-up high-resolution CT/abdomen-pelvic CT showing the increased size of multiple lymph node metastases, and the patient began to undergo Viscum album therapy (0.2 mg, subcutaneously, three times a week). After the V. album therapy was initiated, a decrease in the size of metastatic lymph nodes and CA19-9 level, which was decreased to 252 U/mL, was observed. Seventeen months after continuous V. album therapy, the patient agreed to have palliative chemotherapy. The patient underwent gemcitabine plus cisplatin chemotherapy and showed stable disease during follow-up. This case report suggests that V. album therapy showed anticancer effects and may act as a bridge to palliative chemotherapy for patients with inappropriate general conditions to undergo chemotherapy for recurrent gallbladder cancer.
Identifiants
pubmed: 38229495
pii: kjco.23016
doi: 10.14216/kjco.23016
doi:
Types de publication
Journal Article
Langues
eng
Pagination
88-92Subventions
Organisme : Abnoba Korea
ID : 4-2021-0077